Defining low and undetectable levels of disease in chronic myeloid leukemia:progress towards standardisation in Europe

Autor: H. White, F. Lin, A. Aggerholm, H. Andrikovics, G. Barbany, N. Boeckx, J. M. Cayuela, D. Colomer, F. Daraio, S. Dulucq, H. El Housni, G. Gerrard, E. Gineikiene, S. Hayette, M. Jansson, P. Johnels, T. Jurcek19, V. Kairisto20, T. Lange21, T. Lion22, K. Machova23, G. Martinelli, PA Merle, G. Mitterbauer Hohendanner, M. Nagar Marciano, J. Nomdedeu, D. A. Nymoen, E. Oppliger Leibundgut, U. Ozbek, T. Pajic, C. Preudhomme33, K. Raudsepp34, T. Sacha35, R. Talmaci36, T. Touloumenidou, VHJ Van der Velden, R. Zadro, J. Ziermann, K. Zoi, MC Müller, A. Hochhaus, NCP Cross, IZZO, BARBARA

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3730::a07e071d43897f4718aad7c148a45321
http://hdl.handle.net/11588/598800

T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis

Autor: Jjm van Dongen, Vhj van der Velden, J M Wijkhuijs, Dch Jacobs, E. R. Van Wering

Publikováno v: Leukemia, 16, 1372-1380. Nature Publishing Group

Several studies have shown that quantitative detection of minimal residual disease (MRD) predicts clinical outcome in childhood acute lymphoblastic leukemia (ALL). In this report we investigated the applicablility of T cell receptor gamma (TCRG) gene

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78979ec5182ceefa7614e514ac8e6ec6
https://doi.org/10.1038/sj.leu.2402515

Mutational mechanisms in multiply relapsed pediatric acute lymphoblastic leukemia.

Autor: van der Ham CG; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Suurenbroek LC; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Kleisman MM; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Antić Ž; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Lelieveld SH; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Yeong M; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Westera L; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Dutch Childhood Oncology Group, Utrecht, The Netherlands., Sonneveld E; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Dutch Childhood Oncology Group, Utrecht, The Netherlands., Hoogerbrugge PM; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Dutch Childhood Oncology Group, Utrecht, The Netherlands., van der Velden VHJ; Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands., van Leeuwen FN; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Kuiper RP; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. r.kuiper@prinsesmaximacentrum.nl.; Department of Genetics, Utrecht University Medical Center, Utrecht University, Utrecht, The Netherlands. r.kuiper@prinsesmaximacentrum.nl.

Publikováno v: Leukemia [Leukemia] 2024 Nov; Vol. 38 (11), pp. 2366-2375. Date of Electronic Publication: 2024 Sep 04.

MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR and ddPCR.

Autor: Pott C; Second Medical Department, University Hospital Schleswig-Holstein, Kiel, Germany. c.pott@med2.uni-kiel.de., Brüggemann M; Second Medical Department, University Hospital Schleswig-Holstein, Kiel, Germany., Ritgen M; Second Medical Department, University Hospital Schleswig-Holstein, Kiel, Germany., van der Velden VHJ; Department of Immunology, Erasmus MC, Erasmus University Medical Center, Rotterdam, The Netherlands., van Dongen JJM; Centro de Investigación del Cáncer-Instituto de Biología Molecular y Celular del Cáncer (CIC-IBMCC, USAL-CSIC-FICUS) and Department of Medicine, University of Salamanca, Salamanca, Spain.; European Scientific foundation for Laboratory Hemato Oncology (ESLHO), Zutphen, The Netherlands.

Publikováno v: Methods in molecular biology (Clifton, N.J.) [Methods Mol Biol] 2025; Vol. 2865, pp. 189-219.

Minimal residual disease assessment in B-cell precursor acute lymphoblastic leukemia by semi-automated identification of normal hematopoietic cells: A EuroFlow study.

Autor: Verbeek MWC; Laboratory for Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands., Rodríguez BS; Translational and Clinical Research program, Cancer Research Centre (IBMCC, CSIC-USAL), Cytometry Service, NUCLEUS, Salamanca, Spain.; Department of Medicine, University of Salamanca (USAL), Salamanca, Spain.; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain., Sedek L; Department of Microbiology and Immunology, Medical University of Silesia in Katowice, Zabrze, Poland.; Department of Pediatric Hematology and Oncology, Zabrze, Medical University of Silesia in Katowice, Katowice, Poland., Laqua A; Department of Hematology, University of Schleswig-Holstein, Kiel, Germany., Buracchi C; Centro Tettamanti, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy., Buysse M; Department of Diagnostic Sciences, Ghent University, Ghent, Belgium.; Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium., Reiterová M; CLIP-Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic., Oliveira E; Pediatrics Institute IPPMG, Faculty of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil., Morf D; Institute for Laboratory Medicine, Aarau, Switzerland., Oude Alink SR; Laboratory for Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands., Barrena S; Translational and Clinical Research program, Cancer Research Centre (IBMCC, CSIC-USAL), Cytometry Service, NUCLEUS, Salamanca, Spain.; Department of Medicine, University of Salamanca (USAL), Salamanca, Spain.; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain., Kohlscheen S; Department of Hematology, University of Schleswig-Holstein, Kiel, Germany., Nierkens S; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Hofmans M; Department of Diagnostic Sciences, Ghent University, Ghent, Belgium.; Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium., Fernandez P; Institute for Laboratory Medicine, Aarau, Switzerland., de Costa ES; Pediatrics Institute IPPMG, Faculty of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil., Mejstrikova E; CLIP-Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic., Szczepanski T; Department of Pediatric Hematology and Oncology, Zabrze, Medical University of Silesia in Katowice, Katowice, Poland., Slota L; Department of Pediatric Hematology and Oncology, Zabrze, Medical University of Silesia in Katowice, Katowice, Poland., Brüggemann M; Department of Hematology, University of Schleswig-Holstein, Kiel, Germany., Gaipa G; Centro Tettamanti, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy., Grigore G; Cytognos SL, Salamanca, Spain., van Dongen JJM; Translational and Clinical Research program, Cancer Research Centre (IBMCC, CSIC-USAL), Cytometry Service, NUCLEUS, Salamanca, Spain.; Department of Medicine, University of Salamanca (USAL), Salamanca, Spain.; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.; Department of Immunology, Leiden University Medical Center (LUMC), The Netherlands., Orfao A; Translational and Clinical Research program, Cancer Research Centre (IBMCC, CSIC-USAL), Cytometry Service, NUCLEUS, Salamanca, Spain.; Department of Medicine, University of Salamanca (USAL), Salamanca, Spain.; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain., van der Velden VHJ; Laboratory for Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Publikováno v: Cytometry. Part B, Clinical cytometry [Cytometry B Clin Cytom] 2024 Jul; Vol. 106 (4), pp. 252-263. Date of Electronic Publication: 2023 Sep 22.